ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0147

The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
Abstract Number: 0074

The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons
Abstract Number: 1398

The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
Abstract Number: 0557

The Joint Association of Steps/day and Typical Sedentary Bout Length with Worsening Knee Cartilage Damage over Two Years: The MOST Study
Abstract Number: 0311

The Link Between Joints and Entheses in Psoriatic Arthritis: An Ultrasound Study Supporting the Synovio-entheseal Complex Theory
Abstract Number: 0299

The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Abstract Number: 0704

The Murine Ear Wound Cartilage Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Following Cecal Transplantation
Abstract Number: 1440

The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Abstract Number: 1027

The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017
Abstract Number: 0270

The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Abstract Number: 1532

The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1
Abstract Number: 0186

The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Abstract Number: 1123

The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty
Abstract Number: 0570

The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Abstract Number: 1754

The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].